Literature DB >> 17636410

The protein kinase C inhibitor, H7, inhibits tumor cell invasion and metastasis in mouse melanoma via suppression of ERK1/2.

Masanobu Tsubaki1, Hiroshi Matsuoka, Chikako Yamamoto, Chisato Kato, Mitsuhiko Ogaki, Takao Satou, Tatsuki Itoh, Takashi Kusunoki, Yoshihiro Tanimori, Shozo Nishida.   

Abstract

Protein kinase C (PKC) has been shown to be a signal transducer during tumorigenesis, tumor cell invasion, and metastasis. Recent studies have reported that the PKC inhibitor, 7-hydroxystaurosporine, inhibits tumor cell invasion. However, the molecular mechanisms of this inhibition of invasion and metastasis are not well understood. In the present study, we attempt to clarify the mechanism by which H7, a PKC inhibitor, inhibits tumor cell invasion and metastasis in the melanoma cell line B16BL6. It was found that H7 inhibits B16BL6 cell invasion and metastasis. We also observed that H7 inhibits the mRNA expression and protein activities of matrix metalloproteinase (MMP)-1, -2, -9 and MT1-MMP. Furthermore, H7 suppresses phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2). However, other signal transduction factors, such as p38 mitogen-activated protein kinase (p38MAPK) and c-Jun N-terminal kinase 1/2 (JNK1/2), were unaffected. Moreover, U0126, a MEK1/2 inhibitor, also inhibited B16BL6 cell invasion and metastasis, as well as the mRNA expression and protein activities of MMP-1, -2, -9 and MT1-MMP. This indicates that H7 inhibits signal transduction through the PKC/MEK/ERK pathway, thereby inhibiting B16BL6 cell invasion and metastasis. These results suggest that PKC inhibitors have potential clinical applications in the treatment of tumor cell metastasis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17636410     DOI: 10.1007/s10585-007-9080-z

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  28 in total

1.  Ectopic alphaIIbbeta3 integrin signaling involves 12-lipoxygenase- and PKC-mediated serine phosphorylation events in melanoma cells.

Authors:  E Rásó; J Tóvári; K Tóth; S Paku; M Trikha; K V Honn; J Tímár
Journal:  Thromb Haemost       Date:  2001-06       Impact factor: 5.249

2.  Myricetin inhibits matrix metalloproteinase 2 protein expression and enzyme activity in colorectal carcinoma cells.

Authors:  Ching-Huai Ko; Shing-Chuan Shen; Tony J F Lee; Yen-Chou Chen
Journal:  Mol Cancer Ther       Date:  2005-02       Impact factor: 6.261

3.  Protein kinase C-alpha activity inversely modulates invasion and growth of intestinal cells.

Authors:  E Batlle; J Verdú; D Domínguez; M del Mont Llosas; V Díaz; N Loukili; R Paciucci; F Alameda; A G de Herreros
Journal:  J Biol Chem       Date:  1998-06-12       Impact factor: 5.157

Review 4.  Development of matrix metalloproteinase inhibitors in cancer therapy.

Authors:  M Hidalgo; S G Eckhardt
Journal:  J Natl Cancer Inst       Date:  2001-02-07       Impact factor: 13.506

Review 5.  Matrix metalloproteinases in human melanoma.

Authors:  U B Hofmann; J R Westphal; G N Van Muijen; D J Ruiter
Journal:  J Invest Dermatol       Date:  2000-09       Impact factor: 8.551

6.  Effect of 7-hydroxystaurosporine on glioblastoma cell invasion and migration.

Authors:  Qing-hui Meng; Li-xin Zhou; Jia-lin Luo; Jian-ping Cao; Jian Tong; Sai-jun Fan
Journal:  Acta Pharmacol Sin       Date:  2005-04       Impact factor: 6.150

7.  Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A.

Authors:  Michael W Yeh; Jean-Philippe Rougier; Jin-Woo Park; Quan-Yang Duh; Mariwil Wong; Zena Werb; Orlo H Clark
Journal:  Endocr Relat Cancer       Date:  2006-12       Impact factor: 5.678

Review 8.  Protein kinase C in melanoma.

Authors:  Masahiro Oka; Ushio Kikkawa
Journal:  Cancer Metastasis Rev       Date:  2005-06       Impact factor: 9.264

9.  Induction of membrane-type-1 matrix metalloproteinase by epidermal growth factor-mediated signaling in gliomas.

Authors:  Timothy E Van Meter; William C Broaddus; Harcharan K Rooprai; Geoffrey J Pilkington; Helen L Fillmore
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

10.  Motility analysis of pancreatic adenocarcinoma cells reveals a role for the atypical zeta isoform of protein kinase C in cancer cell movement.

Authors:  Carlo Laudanna; Claudio Sorio; Cristina Tecchio; Eugene C Butcher; Antonio Bonora; Claudio Bassi; Aldo Scarpa
Journal:  Lab Invest       Date:  2003-08       Impact factor: 5.662

View more
  10 in total

1.  Protein kinase Cα (PKCα) regulates p53 localization and melanoma cell survival downstream of integrin αv in three-dimensional collagen and in vivo.

Authors:  Stephen D Smith; Martin Enge; Wenjie Bao; Minna Thullberg; Tânia D F Costa; Helene Olofsson; Behxhet Gashi; Galina Selivanova; Staffan Strömblad
Journal:  J Biol Chem       Date:  2012-07-06       Impact factor: 5.157

2.  Adenosine A(3) receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity.

Authors:  Sarvesh Jajoo; Debashree Mukherjea; Kounosuke Watabe; Vickram Ramkumar
Journal:  Neoplasia       Date:  2009-11       Impact factor: 5.715

3.  Statins improve survival by inhibiting spontaneous metastasis and tumor growth in a mouse melanoma model.

Authors:  Masanobu Tsubaki; Tomoya Takeda; Toshiki Kino; Naoya Obata; Tatsuki Itoh; Motohiro Imano; Kenji Mashimo; Daichiro Fujiwara; Katsuhiko Sakaguchi; Takao Satou; Shozo Nishida
Journal:  Am J Cancer Res       Date:  2015-09-15       Impact factor: 6.166

4.  Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma.

Authors:  Magdalena B Wozniak; Raquel Villuendas; James R Bischoff; Carmen Blanco Aparicio; Juan F Martínez Leal; Paloma de La Cueva; Ma Elena Rodriguez; Beatriz Herreros; Daniel Martin-Perez; Maria I Longo; Marta Herrera; Miguel A Piris; Pablo L Ortiz-Romero
Journal:  Haematologica       Date:  2010-02-04       Impact factor: 9.941

5.  Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits tumor metastasis in mouse melanoma through suppression of the Rho/ROCK pathway.

Authors:  Yoshihiro Tanimori; Masanobu Tsubaki; Yuzuru Yamazoe; Takao Satou; Tatsuki Itoh; Yasuhiro Kidera; Masahi Yanae; Chikako Yamamoto; Junichi Kaneko; Shozo Nishida
Journal:  Clin Exp Metastasis       Date:  2010-07-15       Impact factor: 5.150

6.  Targeting migration inducting gene-7 inhibits carcinoma cell invasion, early primary tumor growth, and stimulates monocyte oncolytic activity.

Authors:  Aaron P Petty; Stephen E Wright; Kathleen A Rewers-Felkins; Michelle A Yenderrozos; Beth A Vorderstrasse; J Suzanne Lindsey
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

7.  Galangin, a novel dietary flavonoid, attenuates metastatic feature via PKC/ERK signaling pathway in TPA-treated liver cancer HepG2 cells.

Authors:  Shang-Tao Chien; Ming-Der Shi; Yi-Chieh Lee; Chou-Chia Te; Yuan-Wei Shih
Journal:  Cancer Cell Int       Date:  2015-02-04       Impact factor: 5.722

8.  Involvement of tyrosine-specific protein kinase and protein kinase C in J774A.1 macrophage functions activated by Tinospora cordifolia.

Authors:  Priti More; Kalpana Pai
Journal:  J Ayurveda Integr Med       Date:  2017-06-07

Review 9.  Targeting GPCRs and Their Signaling as a Therapeutic Option in Melanoma.

Authors:  Jérémy H Raymond; Zackie Aktary; Lionel Larue; Véronique Delmas
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

10.  Combination therapy of PKCζ and COX-2 inhibitors synergistically suppress melanoma metastasis.

Authors:  Ping Zhou; Jiaqi Qin; Yuan Li; Guoxia Li; Yinsong Wang; Ning Zhang; Peng Chen; Chunyu Li
Journal:  J Exp Clin Cancer Res       Date:  2017-09-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.